TITLE

Functional map completed

AUTHOR(S)
Dorey, Emma
PUB. DATE
March 2000
SOURCE
Nature Biotechnology;Mar2000, Vol. 18 Issue 3, p246
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the completion of the first functional genomics map of an entire genome by Connecticut-based Curagen Corp. in collaboration with Stanley Fields at the University of Washington, Seattle, Washington. Analysis of protein interactions in the yeast Saccharomyces cerevisiae; Implications of the gene mapping on the company's stock price.
ACCESSION #
8831013

 

Related Articles

  • CuraGen Gets Patents on Interactions Implicated in Cancer.  // Biotech Business;Mar2000, Vol. 13 Issue 3, p2 

    Reports that the United States Patent Office has granted two patents for CuraGen Corporation covering human protein interactions that have been implicated in the division and proliferation of cancer cells.

  • CuraGen launches subsid. Grisham, Julie // Nature Biotechnology;Jul2000, Vol. 18 Issue 7, p700 

    Report on the launch of corporations to develop technologies for use in drug discovery, preclinical development and pharmacogenetics by New Haven, Connecticut-based CuraGen Corp. Possible development of software for using entire genome knowledge; Details of stakes of CuraGen.

  • CuraGen reports revenue increased 63% last year.  // Biotech Financial Reports;Mar2000, p1 

    Reports on the financial performance posted by New Haven, Connecticut-based biotechnology firm CuraGen Corp. for the fourth quarter and the year ended December 31, 1999. Pharmaceutical companies with which CuraGen established collaborations; Asset impairment charge; Application of genomics to...

  • CuraGen Shifts Focus, Cuts Jobs.  // Chemical Market Reporter;11/11/2002, Vol. 262 Issue 17, p4 

    Reports the reorganization at CuraGen Corp. as part of their drug development initiatives.

  • Curagen lays down markers, 120,000 of them. Hodgson, John // Nature Biotechnology;Oct99, Vol. 17 Issue 10, p951 

    Focuses on the database possessed by the Curagen Corp. that compiles several single-nucleotide polymorphisms and markers from human genome. Plans of the company to acquire patents for its database; Several associate companies of Curagen that take part in its research projects; Response of...

  • Targeting Growth.  // Pharmaceutical Executive;May2001, Vol. 21 Issue 5, p128 

    Reports on the discovery of a fibroblast growth factor protein by scientists at CuraGen in 2001.

  • News in brief.  // Nature;2/17/2000, Vol. 403 Issue 6771, p696 

    Reports on developments in scientific research as of February 17, 2000. European Commission's setting up of a benchmarking system to compare the scale and quality of research in the member countries of the European Union; Launching of the PubMed Central which gives access to the full text of...

  • Bayer, CuraGen in $1.5 Bn Drug Deal. Jarvis, Lisa // Chemical Market Reporter;01/22/2001, Vol. 259 Issue 4, p3 

    Provides information on an agreement of Bayer AG with CuraGen Corp. Terms of agreement; Remarks from Wolfgang Hartwig, executive vice-president of pharmaceuticals research at Bayer; Goals of the agreement.

  • Alexion and CuraGen form joint venture to develop products.  // Fairfield County Business Journal;5/13/2002, Vol. 41 Issue 19, p26 

    Reports on the joint venture between Alexion Pharmaceutical Inc. and CuraGen Corp. in Connecticut. Benefits of the venture for the companies; Terms of the agreement; Business operations of the company.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics